Stock News

Kinaxis: A Software Asset with Potential Challenges and Opportunities Kinaxis is a best-in-class software asset in a strategically important category, specializing in supply chain planning. However, the company has been plagued by years of poor execution and mismanagement under the current board’s supervision. With the recent abrupt departures of Kinaxis’s Chief Executive Officer and Chief…

Exciting Leadership Changes at Intuitive Machines September 09, 2024 Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) Intuitive Machines, Inc., a prominent space exploration, infrastructure, and services company, recently announced some significant leadership changes that are set to take effect on September 16, 2024. Pete McGrath, the current Senior Vice President and Chief Operating Officer, will be…

Dry Eye Disease (DED) and Other Exciting Developments in Biopharmaceutical Research In recent news, Palatin Technologies, Inc. has announced updates on their clinical programs and strategic priorities, highlighting upcoming milestones in the field of biopharmaceutical research. One of the key areas of focus for the company is Dry Eye Disease (DED), with the PL9643 MELODY-2…

Itafos Inc. Announces Refinancing and Amendment of Credit Facilities Exciting News for Itafos Inc. On September 9, 2024, Itafos Inc. (TSX-V: IFOS) made a significant announcement that has the potential to shape the future of the company. Itafos disclosed that it has entered into an amendment of its existing credit facilities with a syndicate of…

Welcome to the Iron Drone Raider Revolution! Iron Drone Raider: The Future of Counter-Drone Technology Iron Drone Raider Systems – A Game-Changer in Military Defense When it comes to cutting-edge technology, Ondas Autonomous Systems Inc is at the forefront of innovation. With the recent announcement of their largest order ever for the Iron Drone Raider…

CureVac Announces First Clinical Data from CVGBM Cancer Vaccine Study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company specializing in messenger ribonucleic acid (“mRNA”) based medicines, has revealed that the initial clinical findings from their Phase 1 CVGBM cancer vaccine study in patients with resected…

Positive Results from Terns Pharmaceuticals Phase 1 Trial for TERN-601 Statistically Significant Weight Loss and Well-Tolerated Drug Terns Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 1 trial for TERN-601. The trial showed statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo adjustment. This is a…

Welcome to MoonLake Immunotherapeutics’ Capital Markets Update! What to Expect Get ready for an exciting event as MoonLake Immunotherapeutics AG gears up to host a Capital Markets Update for investors and analysts. This live event will take place on Wednesday, September 11, 2024, from 9:00 – 10:30 EST in New York, and will feature key…